[Intravitreal bevacizumab for choroidal neovascularization associated with Best's disease]

Arch Soc Esp Oftalmol. 2014 Oct;89(10):405-7. doi: 10.1016/j.oftal.2013.07.002. Epub 2014 Feb 5.
[Article in Spanish]

Abstract

Case report: A 27-year old woman presented with loss of vision in the right eye (20/200). Ophthalmoscopic examination showed intrarretinal hemorrhage in the macular region with neurosensory detachment in the right eye, and viteliform deposit on the left eye. Fluorescein angiography and the electrooculogram confirmed the diagnosis of choroidal neovascularization associated with Best's disease. Four weeks after a single bevacizumab intravitreal injection, visual acuity was restored (20/25) and remained stable after a 12 month follow-up.

Discussion: Intravitreal bevacizumab appears to be an effective treatment for choroidal neovascularization associated to Best's disease.

Keywords: Best's disease; Best's vitelliform macular dystrophy; Bevacizumab; Choroidal neovascularization; Distrofia macular viteliforme de Best; Enfermedad de Best; Intravitreal injection; Inyección intravítrea; Neovascularización coroidea.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Angiogenesis Inhibitors / administration & dosage*
  • Bevacizumab / administration & dosage*
  • Choroidal Neovascularization / complications*
  • Choroidal Neovascularization / drug therapy*
  • Female
  • Humans
  • Intravitreal Injections
  • Vitelliform Macular Dystrophy / complications*

Substances

  • Angiogenesis Inhibitors
  • Bevacizumab